Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02565433
Other study ID # PRAMECE-1302
Secondary ID
Status Terminated
Phase N/A
First received
Last updated
Start date November 2013
Est. completion date June 2018

Study information

Verified date October 2018
Source Centre Oscar Lambret
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to assess prospectively the impact of radiosurgery on the quality of life in patients with brain metastases.


Description:

The patients who meet the selection criteria and who have accepted to participate at the study will answer different questionnaires of the study before radiosurgery and at 3, 6, 9 and 12 months after the treatment of brain metastases. Baseline examinations will be done before receiving the treatment during the hospitalisation for the Gamma Knife treatment, and then they will be repeated at the evaluation visits which are classically done every 3 months. MRI's will also be performed every 3 months. In this way, no additional travel or MRI will be carried out as part of the study.


Recruitment information / eligibility

Status Terminated
Enrollment 52
Est. completion date June 2018
Est. primary completion date January 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient with newly diagnosed brain metastases

- Patient with cancer regardless of the type of primary cancer, with anatomopathological proof

- At least, one measurable lesion = 10 mm on the MRI T1 gadolinium sequences

- Number of brain metastases lower or equal to 5

- Indication of radiosurgery treatment

- Age = 18 years old

- ECOG-PS 0-2

- Expected survival > 3 months

- Ability to complete self-administered questionnaires. If the patient has a motor disability (hemibody deficit) that does not allow to complete himself the questionnaires, these will be read by a CRA of the Neurosurgery department who will outline the questions without making any comment.

- A non-opposition form must have been completed by the patient

Exclusion Criteria:

- Previous cancer (< 5 years) except of carcinoma of cervix uteri, basal cell or squamous cell skin carcinoma adequately treated

- Previous brain radiotherapy

- Neurological pathology with cognitive disorders existing before the study

- Having a contraindication for MRI

- Associated leptomeningeal disease

- Patients having another severe or uncontrolled pathology which could compromise the participation at the study (such as infection, cardiovascular, digestive, renal or pulmonary disease)

- Pregnant or breastfeeding woman. The women must not breastfeed for at least 6 months

- Impossibility to submit to the medical examinations of the study due to geographic, social or mental reasons

Study Design


Intervention

Other:
questionnaire administration
Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale

Locations

Country Name City State
France CHRU de Lille - Hôpital Salengro Lille

Sponsors (2)

Lead Sponsor Collaborator
Centre Oscar Lambret Centre Hospitalier Universitaire de Besancon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Impact at 6 months of the radiosurgery based on the evaluation of 4 criteria of the QLQ C30 questionnaire The 4 criteria are the perceived overall state, health, physical functioning, cognitive functioning and tiredness 6 months
Secondary Comparison of the scores obtained on the scales, questionnaires and Performance status at baseline and every 3 months (until 12 months) after Gamma Knife treatment QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition), ESAS (quality of life), Performance status (OMS) 1 year
Secondary Comparison of the scores obtained on the scales and questionnaires according to the type of primary cancer at baseline and every 3 months (until 12 months) after Gamma Knife treatment QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition) 1 year
Secondary Comparison of the scores obtained on different scales according to the type of associated treatments at baseline and every 3 months (until 12 months) after Gamma Knife treatment The type of associated treatments are: chemotherapy, targeted therapy, corticoids, anti-epileptics, psychotropic drugs.
The different scales are QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), ESAS (quality of life) and MoCA (cognition)
1 year
Secondary Correlation between the scores obtained on the different scales at the baseline and the progression-free survival / overall survival 1 year
Secondary Correlation between the scores obtained on the scales QLQ C30, BN20 (quality of life), IADL (autonomy), HADS (anxiety-depression), MoCA (cognition), ESAS (quality of life) at baseline and those obtained at 3, 6, 9, 12 months 1 year
Secondary Correlation between the scores obtained on the scales during the study and the clinical neurological response at baseline and every 3 monts until 12 months after Gamma Knife treatment The correlation will take into account the evolution of the systemic disease and the volumetric tumor response. Volumetric tumor responses will be calculated on the MRI's 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02953756 - Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
Completed NCT00184353 - Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T. N/A
Recruiting NCT02789371 - Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions N/A
Completed NCT01122199 - Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors Phase 1
Terminated NCT01336985 - Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads Phase 1
Recruiting NCT05419518 - Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas Phase 2
Completed NCT02808416 - Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) Phase 1
Completed NCT00668382 - Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Phase 1
Completed NCT00152906 - Stereotactic Radiotherapy (SRT) Liver (COLD 1) Phase 1/Phase 2
Completed NCT01267084 - A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1/Phase 2
Recruiting NCT02327065 - Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion N/A
Completed NCT02382653 - Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain N/A
Completed NCT01273480 - A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1
Completed NCT01273493 - A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction Phase 1
Completed NCT00556049 - Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT02246634 - Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) N/A
Terminated NCT01970644 - Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases N/A